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Research
AbstrACt
Objectives To describe the experiences of the HIV 
treatment cascade of diagnosis, engagement with care 
and initiation of treatment from the perspective of patients; 
we explored whether this differed according to the year of 
their diagnosis, for example, whether they had experienced 
HIV care in the pretreatment era.
Design Qualitative interview study with framework 
analysis.
setting Two large HIV adult outpatient clinics in central 
London.
Participants 52 HIV-positive individuals, 41 men, 11 
women, purposively sampled to include people who 
had been diagnosed at different stages in the history of 
the epidemic classified as four ‘generations’: pre-1996 
(preantiretroviral therapy (ART)), 1997–2005 (complex 
ARTs), 2006–2012 (simpler ARTs) and 2013 onwards 
(recent diagnoses).
results Some important differences were identified; 
for earlier generations, the visible illness and deaths 
from AIDS made it harder to engage with care following 
diagnosis. Subsequent decisions about starting treatment 
were deeply influenced by the fear of severe side effects 
from early ART. However, despite improvements in ART 
and life expectancy over the epidemic, we found a striking 
similarity across participants’ accounts of the key stages 
of the care continuum, regardless of when they were 
diagnosed. Diagnosis was a major traumatic life event 
for almost everyone. Fear of testing positive or having 
low self-perceived risk affected the timing of testing and 
diagnosis. Engaging with care was facilitated by a flexible 
approach from services/clinicians. Initiating treatment was 
a major life decision.
Conclusion We found patients’ experiences are 
influenced by when they were diagnosed, with earliest 
cohorts facing substantial challenges. However, being 
diagnosed with HIV and starting treatment continue to be 
significant life-altering events even in the era of effective, 
simple treatments. Despite the advances of biomedical 
treatment, services should continue to recognise the needs 
of patients for whom the diagnosis and treatment remain 
significant challenges.
IntrODuCtIOn
The HIV continuum of care provides step-
wise estimates for the stages of engagement 
in care for people living with HIV (PLHIV).1 
The Joint United Nations Programme on HIV 
and AIDS’s goal to end the AIDS epidemic by 
2020 stipulates a target of 90% of all people 
with HIV be diagnosed, of whom 90% are on 
antiretroviral therapy (ART), of whom 90% 
(73% of PLHIV) are virally suppressed.2 The 
UK has one of the best outcomes for HIV 
treatment and care in the world with an esti-
mated 78% of PLHIV having an undetectable 
viral load.3 4 However, the statistics do not and 
cannot tell us about the patient experience of 
passing through these stages of care whether 
it be good or bad. The continuum essentially 
measures the success of programmes from a 
provider rather than a patient perspective.5 
Flowers et al4 argue that there is a tension 
between the certainty and confidence of a 
linear HIV pathway, associated with ideas of 
clinical efficacy, and patient experiences of 
strengths and limitations of this study
 ► The large number of participants at two different 
clinics and the inclusion of a range of people with 
HIV, broadly similar to the clinic cohorts, across four 
HIV ‘generations’.
 ► The interview format allowed us to explore factors 
important to participants rather than asking about 
predefined concerns.
 ► An imbalance between generations, with larger 
numbers of women in the earliest two generations 
and only one woman in the generation recently 
diagnosed. This means that some of our conclu-
sions about generations may also reflect gendered 
differences.
 ► Our recruitment methods meant we were not able 
to explore the experiences of those who remain out-
side care.
 ► Limitation of the single-interview format means 
people were having to recall past experiences, some 
of which were three decades ago. This may have 








pen: first published as 10.1136/bmjopen-2017-020208 on 30 March 2018. Downloaded from 
2 Bruton J, et al. BMJ Open 2018;8:e020208. doi:10.1136/bmjopen-2017-020208
Open Access 
diagnosis and prognosis, which can be full of uncertainty. 
With the evolution of modern ARTs, we have witnessed 
the transformation of HIV from an acute life-threat-
ening infection to a treatable chronic condition and a 
concurrent evolving of the care continuum. However, it 
is unclear whether this change is reflected in patients’ 
own experiences of passing through each of the stages 
of care. For example, has the moment of diagnosis 
become any less traumatic, and have decisions about 
starting treatment become simpler for patients? Analysis 
of patient narratives, historically and currently, may help 
to highlight significant factors for patients in the care 
continuum. This is particularly important in a climate 
of National Health Service restructuring in the UK, 
which has led to reductions in non-clinical services and 
streamlining of care. To this end, we explored the patient 
perspectives on the care continuum, and we hypothesised 
that patients’ experiences of, and engagement with, care 
would differ according to what point in the epidemic they 
were diagnosed.
MethODs
We undertook a qualitative study of people attending two 
public HIV clinics in London that have provided care 
since the start of the epidemic; they were also chosen 
for their large size and diversity, in terms of demo-
graphics. They are both specialist HIV clinics linked to 
sexual health (genitourinary medicine) services. Care is 
provided by physician-led multidisciplinary teams where 
patients have a named consultant. HIV care in the UK 
is free and open access, allowing patients to register at 
their clinic of choice. We used a purposive sampling 
method to recruit patients with a range of experiences. 
To reflect the evolution of ART, we identified four ‘gener-
ations’ according to time of diagnosis: pre-1996 (pre-
ART), 1997–2005 (complex ARTs), 2006–2012 (simpler 
ARTs) and 2013 onwards (recent diagnoses). Within each 
generation, we aimed to include people with a range 
of characteristics, including, gender, exposure, age and 
ethnicity. Participants were recruited opportunistically by 
researchers attending clinical services and through fliers 
and digital advertising in clinical areas. Recruitment was 
periodically checked against the recruitment matrix and 
under-represented groups/strata targeted.
Patients were provided with information and gave 
written consent. Interviews took place in private rooms 
in or near the clinics or at the patient’s home; they were 
recorded and transcribed, and interviews lasted between 
60 and 90 minutes. The interviews were semistructured 
and carried out by one male (CH) and three female 
researchers (JB, TR and JR), three of whom had clinical 
backgrounds. The interviews were based on a topic guide 
(see online supplementary file) informed by a focus 
group of PLHIV who assisted in designing the research. 
We invited participants to recall their initial diagnosis 
and describe key points in their HIV journey including 
testing, disclosure, support, engaging with care, starting 
treatment, medication adherence, work and social life. 
Field notes were written after the interviews.
Transcripts were uploaded to NVivo, a qualitative data 
analysis software package. Using Framework analysis, we 
developed key themes through a systematic process that 
involved reading, rereading, coding and summarising 
the transcripts and and subsequent in-depth analysis of 
the dataset.6 Final themes were discussed in the research 
group (HW, JB, SD and TR) and further analysed in rela-
tion to the existing literature.
results
Fifty-two patients were recruited, 25 at one clinic and 
27 at the other. The sample included 41 men and 11 
women; 37 men acquired HIV through sex with other 
men (MSM), while the rest through heterosexual contact 
(n=14) or injection drug use (n=1). There were 11 in 
generation 1, 14 generation 2, 17 generation 3 and 10 
generation 4. The characteristics of the study participants 
alongside those of the clinic population for 2014 are 
shown in table 1.
The generation samples differed somewhat by gender 
and acquisition: the women were concentrated in gener-
ations 1 and 2 (n=6 and 4, respectively), and MSM in 
generations 3 and 4 (n=16 and 8, respectively).
We have used pseudonyms for each of the following 
quotes from participants.
‘becoming positive’: the impact of hIV diagnosis
The experience of receiving an HIV diagnosis was similar 
across the generations. First reactions were generally of 
shock and fear of death, irrespective of generation. Alan, 
diagnosed in 1991, knew nothing about HIV and had not 
tested before. He remembers vividly the time he received 
his result:
I could hear myself saying ‘I’m going to die’. Not ver-
bally but in my mind, ‘I’m going to die, I’m going to 
die’. (gen 1, MSM)
Sylvia, diagnosed 2001, was ‘totally devastated’:
… I didn’t see myself going back and doing my 
Master’s degree for what reason am I going back to do 
that if I have maybe five years to live. (gen 2, woman)
Roger, diagnosed more than 20 years later, reported 
several previous tests and considered himself 
well informed. However, his principal concern on receiving 
a positive diagnosis was also about life expectancy:
But even I was not certain. Certainty is the wrong 
word. I was under the illusion that my expiry date was 
stamped on me now. (gen 4, MSM)
Fear of a positive result was a key factor in delayed diag-
nosis for several MSM in all generations, who reported 
concerns about the impact of HIV on their lives. They 
were aware of their risk and described feeling relieved at 
diagnosis as HIV had been ‘hanging over them’ for years; 
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the diagnosis confirmed their suspicions. William, who 
had never tested before, presented with symptoms:
[I had been] burying my head in the sand. I guess 
I knew I had it but didn’t, at the same time, want it 
confirmed. (gen 2, MSM)
Brian (gen 4, MSM), recently diagnosed, had ‘spent on 
and off probably eight years thinking about it’. He felt he had 
‘done all the thinking before’so, although disappointed, he 
was also relieved.
Most other participants, particularly heterosexual men 
and women, were not expecting a positive result and had 
not requested an HIV test. They were diagnosed either 
following ongoing symptoms of ill health or having 
presented for a general sexual health check-up.
None of the women had been diagnosed during preg-
nancy; most were diagnosed before antenatal screening 
became routine in the UK (1999). For example, Olivia, 
diagnosed in 1998, had not been tested in pregnancy. 
Her 6-month-old baby became sick, and both baby and 
husband were then diagnosed with HIV but she did not 
believe she had HIV and delayed testing for several weeks.
Me I don’t have HIV because I never went with other 
men. (gen 2, woman)
The response and level of support offered by clini-
cians at this critical time were important to participants’ 
immediate well-being and influenced what happened 
next, including continuing engagement in care. Martha 
remarked:
I remember how lovely [name of clinician] was and 
I’ve always said I could never wish for a better per-
son to ever tell me or try to guide me, or to reassure 
me more than what she did because she was perfect. 
(gen 4, woman)
While most experiences were positive, there were some 
exceptions. Paul (gen 3, MSM) had regularly tested nega-
tive but continued to take risks. Testing positive in 2010 
was totally unexpected, leaving him ‘numb with shock’, and 
Table 1 Study sample characteristics compared with the clinic cohorts
Clinic A Clinic B
Study sample 2014 Cohort Study sample 2014 Cohort
n % n % n % n % 
Gender
  Male 18 72.0 2459 77.5 23 85.2 7743 90.3
  Female 7 28.0 715 22.5 4 14.8 830 9.7
Age (years)
  18–24 0 0.0 124 3.9 0 0.0 186 2.2
  25–34 4 16.0 465 14.7 3 11.1 1729 20.2
  35–49 16 64.0 1502 47.3 14 51.9 4164 48.6
  50+ 5 20.0 1083 34.1 10 37.0 2494 29.1
Ethnicity
  White 14 56.0 1541 48.6 22 81.5 6401 74.7
  Black African 5 20.0 720 22.7 5 18.5 778 9.1
  Black Caribbean 0 0.0 114 3.6 0 0.0 201 2.3
  Other/mixed 6 24.0 746 23.5 0 0.0 1132 13.2
  Not reported 0 0.0 53 1.7 0 0.0 61 0.7
Exposure route
  Sex between men 15 60.0 1971 62.1 22 81.5 6776 79.0
  Heterosexual contact 9 36.0 1037 32.7 5 18.5 1209 14.1
  Injecting drug use 1 4.0 52 1.6 0 0.0 109 1.3
  Other 0 0.0 112 3.5 0 0.0 46 0.5
  Undetermined 0 0.0 2 0.1 0 0.0 433 5.1
Year of diagnosis
  Pre-1997 6 24.0 638 20.1 5 18.5 1399 16.3
  1997–2005 6 24.0 1234 38.9 8 29.6 2580 30.1
  2006–2012 7 28.0 986 31.1 10 37.0 3199 37.3
  2013 onwards 6 24.0 316 10.0 4 14.8 1395 16.3
  Total 3174 8573
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he did not feel that he was supported appropriately. The 
clinician who gave him the diagnosis seemed ‘[to be on] 
autopilot because he had seen people like me before’ and was 
‘working to his own agenda’. Despite Paul’s obvious distress, 
the clinician asked him to ring potential contacts during 
the consultation. Furthermore, when the clinician said: 
‘Oh this can be managed, don’t worry’, Paul interpreted this 
to mean ‘managed to his death’. After 2 weeks of acute 
anxiety, Paul contacted a friend who was able to reassure 
him about treatment and the care pathway. Similar expe-
riences led other participants to feel vulnerable, isolated 
and slow to accept their diagnosis.
‘becoming an hIV patient’: developing a relationship with 
clinic and clinician
Once diagnosed, participants described a sense of reas-
surance about being in the ‘best hands’, managed by 
experts in HIV medicine. The majority across the gener-
ations described strong relationships with their clinicians 
and valued seeing the same person each visit. It felt ‘like a 
partnership’ with ‘someone you can tell anything’, who knew 
them and their entire history, ensuring that care went 
beyond just the clinical management of HIV: ‘We seriously 
talk about how I am not just what my CD4 count is’.
However, some had not developed a trusting relation-
ship. Marty (gen 3, MSM), for example, diagnosed HIV 
in 2012, was not eligible for treatment under guidelines 
at that point. He described anxiety about this lack of 
treatment, feeling that it adversely affected pre-existing 
mental health problems that were not addressed by his 
clinicians. He attended two different clinics and was on 
the verge of dropping out of care when, as he recounted: 
‘I basically rescued myself’. His friend recommended a clini-
cian: ‘She got me just like that thank god, thank god…I finally 
found and she was willing to fight my case’.
Another participant, Peter, diagnosed in 2009, reported 
changing HIV clinics within 3 months of diagnosis. He 
recalled a series of mistakes, miscommunication and a 
‘dehumanising’ clinic environment. Losing trust in clini-
cians and the service, he finally gained confidence from 
attending a support group and moved his care:
I remember that I said, it was like falling off a build-
ing… I’m slowly falling backwards as the virus in-
creases. It felt like they were holding a blanket at the 
bottom to catch me but it felt like they were holding it 
in the wrong place. I was being asked to trust. (gen 3, 
MSM)
All participants valued continuity of care, although two 
recently diagnosed felt that it was not always necessary to 
see the same clinician. However, continuity was affected 
by what some described as the very busy clinics limiting 
the time for consultations and impeding communication.
All participants were in care at the time of the inter-
view but some described having stayed away in the past. 
Two of six women diagnosed before 1996 had dropped 
out of care for several years. Given the lack of effective 
treatment, they had found clinic visits depressing and 
preferred to keep away until they became sick. Marie 
(gen 1, woman) explained, ‘I didn’t want a life where I just 
would go to tests and I am scared and they had nothing to offer’. 
Alison (gen 1, woman) described the ‘terrible situation’ at 
the clinic, where she saw young gay men, couples, where 
one would be fit and the other ‘in a wheelchair, a skeleton’. 
She felt sorry for the doctors, ‘there were all these poor young 
doctors with nothing to offer and seeing these very ill people’.
Seven of all those diagnosed since ARTs became avail-
able described occasional or multiple lapses in atten-
dance; these were generally explained by issues external 
to the clinic such as recreational drug use, household 
disruption, mental health problems or competing comor-
bidities. Re-engagement with care was easier when their 
clinician actively reached out; for example, some consul-
tants had telephoned patients when they missed appoint-
ments and one woman (gen 1) described interventions 
of this kind as being ‘like my family’. Even though not all 
patients were contacted when they did not attend services, 
and one expressed surprise that no one had tried, all 
found their way back into care.
‘becoming medicalised’: starting treatment
Almost all (48) of the participants were on treatment; one 
had stopped medication because of drug interactions and 
three chose to remain off treatment. Despite the simpli-
fication of regimens, participants in all four generations 
found the decision to start treatment a significant life 
event.
For earlier generations, the decision had been complex 
because of toxicity related to ARTs. Some refused treat-
ment contrary to medical advice. Alison, described 
earlier, recalled, ‘In the waiting rooms people said, “don’t take 
it, it will kill you”, so I refused that (AZT)’. Others felt well 
without treatment like Marie, who was diagnosed in 1986 
but only started ARTs 25 years after diagnosis when her 
CD4 count crashed. She felt she had no choice, ‘I fought 
it all this time on my own, and then finally I had to give in and 
take a pill. That was kind of depressing’.
Those diagnosed more recently found it easier to decide 
to begin treatment, but it was still a significant moment. 
Tim, diagnosed in 2012, was aware of the latest research 
and asked to start treatment immediately, even for him, 
the ‘treatment appointment’ was a sobering experience:
[It was] the only time there was a tear. I just thought, 
God this is a new chapter now. This is a new chapter 
in my life. I am going to have to take this pill for the 
rest of my life. (gen 3, MSM)
Brian, diagnosed in 2013, sums up some of the issues 
that participants said they had considered when deciding 
to start medication:
Well the impact it would have on my life, the dam-
age it would do to my body. Would I cope with the 
medication? Would I be able to continue working? 
Because so many people have side effects initially and 
it takes them a long time to get over. I had a lot of 
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responsibility at work and I couldn’t actually man-
age responsibility well enough once on medication. 
Would I be able to take the medication on time? 
Would life’s pressures allow me to do what I needed 
to do? And so on. (gen 4, MSM)
The three participants not on treatment described 
feeling healthy and wished to remain drug free for as long 
as possible.
For many participants, HIV occupied only a small part 
of their lives, but daily medications proved to be a constant 
reminder of their status even if only for a moment each 
day. Martin, diagnosed in 2014, described his relationship 
with his medication:
It’s strange sometimes because you look at this pill 
and you think between you and this little pill lies – it’s 
keeping you alive. And I have never had a pill to take 
like that before. So, it’s very strange. It’s my friend 
and foe at the same time. (gen 4, MSM)
DIsCussIOn
We have found that patients’ experiences of, and engage-
ment with, care are influenced by the point at which they 
were diagnosed, with the earliest cohorts facing substan-
tial challenges. However, we have also found that being 
diagnosed with HIV and starting treatment continue to 
be significant life-altering events even in the era of effec-
tive and simple treatments. This study brings new insights 
that are important when considering how future services 
should be provided.
The revolution in HIV treatment over three decades 
means it can now be described as a chronic, manageable 
condition.7 8 In our study, all our patients were virally 
suppressed having passed through all the stages of the 
continuum and arrived on the other side. However, 
patients’ recall of their experience of navigating this 
journey revealed a range of quite complex issues faced 
by them at different points, reminding us that many chal-
lenges remain in the successful provision of HIV care. 
We hypothesised that the revolution in treatment would 
have an impact on the experience of the different diag-
nostic generations moving through the care continuum, 
with those diagnosed more recently having a smoother 
journey. We identified some important differences; the 
visible illness and deaths from AIDS made it harder for 
earlier generations to engage with or remain in care and 
some dropped out, returning only when ill. Decisions 
about treatment were particularly difficult for the early 
generations, for whom the association of treatment with 
severe side effects remained strong until more recently 
and who expressed pride in, and determination to, 
remaining well without treatment.
However, our primary finding was a striking similarity 
across participants’ accounts of key stages of the HIV care 
continuum: diagnosis was a major, traumatic life event for 
almost everyone, and anticipation of an HIV-positive status 
affected the timing of testing and diagnosis. Engagement 
with care was facilitated by a responsive, flexible approach 
on the part of services and clinicians, starting with the way 
the positive diagnosis was handled. Finally, initiating treat-
ment was a major life decision even when recommended 
by protocol and considered straightforward by clinicians.
Despite the drive to normalise HIV testing through 
simplified sampling, reduced pretest discussion and 
expanded test settings,9–11 receiving an HIV diagnosis 
remained a significant shock for most participants irre-
spective of generation, sexuality or gender, as suggested 
elsewhere.12–15 Moreover, we found that none of the 
heterosexual participants were expecting a positive result, 
a finding that also applied to some of the MSM partic-
ipants. Resonating with other studies,13 16 17 we found 
that fear of imminent death and experience of profound 
distress did not change, despite the availability of effec-
tive and less toxic treatments. This fear, often coupled 
with a fear of social exclusion and rejection, led some 
MSM participants who suspected they were positive to 
delay testing.18 Bury19 usefully describes this experience 
of illness and especially chronic illness as ‘biographical 
disruption’. When everyday life and its meanings are 
turned upside down, relationships and social networks 
are disrupted, and plans for the future have to be re-ex-
amined.19 Participants described this type of disruption at 
diagnosis, whether HIV was considered an acute infection 
or a chronic condition.
A clinician’s approach to a patient with a positive 
result is considered critical to patients’ experiences 
and may be more important than other aspects of the 
testing process.12 15 17 20 21 We found that negative expe-
riences at this critical point affected immediate well-
being and further contact with services. The impact of 
those initial encounters, both good and bad, left partici-
pants with lasting impressions throughout their journey, 
thus demonstrating the importance of establishing trust 
between clinician and patient as a firm foundation for 
good retention in care.22–24 Women, a minority in the 
clinics and, in our sample mainly from the earlier gener-
ations, faced particular challenges in engaging in care. 
This made the establishment of a trusting relationship 
with their clinician all the more important to managing 
their quality of life with HIV. Moreover, the importance of 
that relationship for participants was underlined by their 
willingness to change their treatment centre until they 
found what they perceived as a good clinician/patient 
relationship. The UK policy of open access to any clinic 
through self-referral may be another explanation for high 
levels of retention in care.
The prospect of treatment for life, to sustain life, was 
a major life event. Currently, the moves towards starting 
treatment at diagnosis, the test-and-treat model, is based 
on the confidence of biomedicine in HIV management 
but may be at odds with patient concerns.25 The British 
HIV Association interim guidelines 2016 recommend 
starting treatment on all diagnosed with HIV regard-
less of CD4 count and continue to recognise that 
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social, psychological, cultural and economic factors can 
adversely affect adherence and treatment outcomes.26 
Starting medication on the same day as, or soon after, 
diagnosis when individuals may be distressed by the posi-
tive result could preclude a meaningful discussion of the 
patient’s ‘readiness to start’. Persson et al’s27 2016 study of 
patients not on ARTs found similar barriers and concerns: 
for example, logistics of starting life-long medication, fear 
of long term side effects and desire to stay drug-free while 
healthy.
Considering ARTs was another point at which some 
participants anticipated ‘biographical disruption’, which 
deterred them from starting treatment.
The study’s strengths are in the large number of partic-
ipants at two different clinics, the inclusion of a range 
of people with HIV broadly similar to the cohorts seen 
at these clinics, and diagnosed across the four genera-
tions. The semistructured interview format allowed us 
to explore factors important to participants rather than 
asking about predefined concerns. However, our study 
sample was imbalanced between generations, with larger 
numbers of women in the earliest two generations and 
only one of those more recently diagnosed. This means 
that some of our conclusions about generation may also 
reflect gendered differences. Our recruitment methods 
that relied on recruitment from the two clinics meant we 
were not able to explore the experiences of those who 
remain outside care. The study is also limited by the single 
interview format that meant people were having to recall 
past experiences, some of which were three decades ago. 
This may have introduced recall bias with subsequent 
experience colouring earlier reports; moreover, earlier 
generations had more time to have disengaged and re-en-
gaged with care. The focus of the study on a particular 
model of care in London limits the generalisability of our 
findings to other settings.
The evolution of simpler treatments has been accompa-
nied by a reconfiguration of the care pathway. In London, 
HIV clinics are increasingly narrowly focused on HIV and 
HIV-specific medications, and clinicians are not autho-
rised to provide more holistic medical care.28 In practice, 
this has led to less frequent clinic visits, a shift to virtual 
‘e-clinics’ and greater links with, and reliance on, general 
practitioners. The impact of this on the care continuum 
is unclear. Continuity of clinician, the atmosphere in the 
clinic and good communication are recognised to be key 
issues for patients.29 30
There is increasing recognition that viral suppression 
is not the final goal for people who are now living longer 
with HIV.31–33 Lazarus et al31 have called for a ‘fourth 90’ 
‘providing an explicit target for health- related quality of 
life’.31 In December 2017, these concerns were embodied 
in policy recommendations from the European Parlia-
ment calling for an integrated and patient-centred 
approach to long-term HIV care ensuring that services 
are meeting this challenge.34 Our study illustrates that 
the patient journey is complex, and personalised care 
should not be lost with streamlining pathways. All our 
participants were virally suppressed but that can hide the 
reality of their reliance on the caregivers to help maintain 
that stability.
A personal, holistic approach has been a hallmark 
of HIV care since the beginning of the epidemic. It is 
important that major advances in biomedical treatment 
do not undermine the care continuum through a loss of 
care that meets the complex needs of patients, for whom 
HIV diagnosis and treatment remain significant chal-
lenges requiring supportive and flexible care.
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